India’s reproductive healthcare landscape is set for a major shift as Intas Pharmaceuticals enters an exclusive collaboration with IntegriMedical to introduce the country’s first Needle-Free Injection System (N-FIS) for IVF and gynecology treatments. The technology is expected to redefine how injectable therapies are administered in fertility care and women’s health.
Under this agreement, Intas becomes the only pharmaceutical company in India authorized to offer IVF and gynecology therapies using needle-free injections. The move establishes a new benchmark in patient-centric drug delivery and reinforces the company’s focus on improving treatment experiences rather than just clinical outcomes.
The partnership will see Intas and IntegriMedical jointly facilitate the adoption of this technology across IVF clinics and gynecology centers nationwide. By using IntegriMedical’s proprietary drug-delivery platform, the initiative aims to reduce injection-related pain and anxiety, helping patients remain more comfortable and confident throughout demanding treatment cycles.
The introduction of needle-free technology is expected to significantly ease treatment fatigue for hundreds of thousands of women.
India is among the world’s fastest-growing IVF markets, currently accounting for an estimated 300,000 to 350,000 treatment cycles annually. Industry projections suggest this number could rise to 500,000 to 600,000 cycles by 2027. With each cycle involving multiple injections, millions of injections are administered every year, making patient comfort a critical concern. The introduction of needle-free technology is expected to significantly ease treatment fatigue for hundreds of thousands of women.
N-FIS administers medication using a high-pressure jet stream that delivers the drug in a precise, spray-like form through a micro-orifice in the skin. This eliminates the need for needles and helps minimize tissue trauma, prevent drug pooling, and reduce the risk of cross-contamination compared to conventional injections.
“It’s incredibly rewarding to see our vision come to life through this groundbreaking collaboration with Intas. For IntegriMedical, this is more than a technical achievement, it’s about making treatments less intimidating, more comfortable, and truly humane. Congratulations to the Intas team for leading this country-first initiative in IVF and gynecology. Together, we are taking a meaningful step forward in putting patients at the heart of care,” said Sarvesh Mutha, Managing Director, IntegriMedical.
Highlighting the broader objective of the collaboration, Durga P Satapathy, Executive Vice President, Intas, said, “This initiative is about more than introducing a new technology; it’s about changing how patients experience care. IVF and gynecology treatments can be demanding, and our goal is to make every step easier, more reassuring, and more dignified. Collaborations like this show what’s possible when innovation is truly focused on people. By leading such patient-centric advancements, we are setting a new benchmark for care in the country.”
By combining Intas Pharmaceuticals’ scale and market leadership with IntegriMedical’s innovation in drug-delivery systems, the partnership marks an important milestone in women’s healthcare, with the potential to transform IVF and gynecology treatment experiences across India.